Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations.
Fotios SampsonasPinelopi BosganaVasiliki BravouArgyrios TzouvelekisFoteinos-Ioannis D DimitrakopoulosEleni KokkotouPublished in: Genes (2024)
NSCLC in patients with Interstitial Lung Disease is a challenging diagnostic and clinical entity, and a personalized medicine approach is fundamental to improving survival and quality of life. Newer anti-fibrotic medications have improved survival in IPF/ILD patients; thus, the incidence of lung cancer is going to vastly increase in the next 5-10 years.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- idiopathic pulmonary fibrosis
- end stage renal disease
- rheumatoid arthritis
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- newly diagnosed
- poor prognosis
- peritoneal dialysis
- prognostic factors
- advanced non small cell lung cancer
- binding protein
- patient reported outcomes
- epidermal growth factor receptor
- tyrosine kinase